Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04650191 · ClinicalTrials.gov registry record
Surfactant Protein Genetic Variants in COVID-19 Infection
A clinical trial, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- 300
- Enrollment target
NCT04650191: Completed study, sponsored by Milton S. Hershey Medical Center.
NCT04650191 is a clinical trial that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04650191 has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric acute lung injury. COVID-19 virus gains entry through the respiratory system and responsible for death due to acute respiratory failure. There is a considerable heterogeneity in presentation of COVID-19 infection from asymptomatic patients to severe infection requiring intensive care and some may die. Considering reports of COVID-19 related deaths/severe disease in the same family, it is possible that genetics play an important role in severity of COVID-19 infection. Investigators propose to study the association of surfactant proteins in COVID-19 patients. Key Objectives: a) Characterize genetic markers within the surfactant protein genes in COVID-19 positive patients, b) To determine if there is a correlation between certain genetic markers and the severity of COVID-19 infection which may be used as a prognostic marker, c) To correlate genetic markers with immune studies.
Interventions
- OTHER Identification of genetic variants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2022-06-30 |
What the finished NCT04650191 record still lists
NCT04650191 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Identification of genetic variants is the first listed.
NCT04650191 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04650191 about?
NCT04650191 is a clinical study titled "Surfactant Protein Genetic Variants in COVID-19 Infection". Surfactant protein plays important role in innate immunity against respiratory viral infections. However, investigators have shown that the surfactant protein polymorphisms are associated with severity of various pulmonary diseases such as respiratory syncytial virus (RSV), tuberculosis, pediatric a...
What is the current status of trial NCT04650191?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2020-03-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04650191?
The interventions under investigation include: Identification of genetic variants (OTHER).
Who is sponsoring clinical trial NCT04650191?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI